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Abstract
Background: Midkine is a heparin-binding cytokine and is involved in etiology of various diseases. Thus, midkine 
inhibitors are expected to be helpful in treatment of many diseases.
Methods: We developed a simple assay for midkine activity based on midkine-dependent migration of osteblastic 
cells. Midkine inhibitors were searched as materials that inhibit this midkine activity. To develop peptides that inhibit 
midkine activity, we constructed models in which C-terminal half of midkine interacted with α4β1-integrin. Low 
molecular weight compounds which are expected to bind to midkine with high affinity were searched by in silico 
screening with the aid of Presto-X2 program.
Results: Among peptides in putative binding sites of midkine and the integrin, a peptide derived from β1-integrin and 
that derived from the first β sheet of the C-terminal half of midkine significantly inhibited midkine activity. Two low 
molecular weight compounds found by in silico screening exhibited no toxicity to target cells, but inhibited midkine 
activity. They are trifluoro compounds: one (PubChem 4603792) is 2-(2,6-dimethylpiperidin-1-yl)-4-thiophen-2-yl-6-
(trifluoromethy)pyrimidine, and the other has a related structure.
Conclusions: The assay procedure is helpful in screening midkine inhibitors. All reagents described here might 
become mother material to develop clinically effective midkine inhibitors.
Background
Midkine is a heparin-binding cytokine of molecular
weight 13 kDa [1-3]. It enhances growth, survival and
migration of various target cells. Midkine has around 50%
sequence identity with pleiotrophin, and the two factors
exhibit overlapping roles in many cases [1,4]. Midkine is
also involved in initiation or progression of many patho-
logical status, such as tumor invasion [5] rheumatoid
arthritis [6], experimental autoimmune encephalitis [7],
adhesion after surgery [8], neointima formation of the
blood vessel [9], hypertension [10], and renal injury after
ischemia [11], exposure to chemotherapeutic reagent [12]
and diabetes [13]. Antisense oligonucleotides or siRNAs
to midkine exhibit therapeutic effects in animal experi-
ments concerning tumor growth [5,14-16], ischemic
renal failure [17], neointima formation [18,19], adhesion
after surgery [20], and antibody-induced arthritis [20]
Polyclonal antibodies to midkine inhibit growth of Wilms'
tumor cells in vitro [21]. Peptides or low molecular
weight compounds are also expected to inhibit midkine
activities, and in many cases these inhibitors might be
superior to antisense oligoDNA or siRNA because of the
ease in the administration methods.
In the present investigation, at first we developed a con-
venient method to screen midkine inhibitors. Then,
applying the assay method, we tried to develop midkine
inhibitors, namely peptides and other low molecular
weight compounds.
Midkine is composed of two domains held by disulfide
bridges. The C-terminal half domain is principally
responsible for midkine activity and its heparin binding
capability [22]. Two heparin binding sites are present in
the C-terminal half [23]. Especially, Arg 81 has been iden-
tified to be important in heparin binding and midkine-
induced neurite outgrowth and migration of neurons
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lar weight compounds, which bind to the C-terminal half.
A rationale to obtain midkine inhibitory peptide should
be based on midkine-receptor interaction. Midkine
receptor is a molecular complex containing proteogly-
cans such as receptor-like protein tyrosine phosphatase
ζ[25], low density lipoprotein receptor-related protein
[26] and integrin α4β1 or α6β1 [27]. A peptide sequence
derived from low density lipoprotein receptor-related
protein has already been utilized to develop an inhibitor
of midkine [28]. In this study we were interested in inter-
action of midkine with α4β1 integrin.
Methods
Materials
Human midkine was produced in yeast as described
before [29]. Candidate inhibitory peptides were synthe-
sized by Peptide Institute, Osaka, Japan, as trifluoroace-
tate salts. Low molecular weight compounds for
screening of midkine inhibitors were purchased from
ChemDiv (San Diego, CA).
Assay of midkine activity
Midkine activity was determined by promotion of migra-
tion of UMR106 (ATTC No. 1661) cells [30]. Chemotaxi-
cell (pore size 8 micron, Kurabo Industries Ltd., Japan)
was coated with 20 μg/ml of midkine at the lower surface
of the filter for 1 h, and washed with Dulbecco's phos-
phate-buffered saline (PBS) twice. UMR106 cells (2 × 105
cells in 0.2 ml of Dulbecco's modified Eagle's medium
with 0.3% bovine serum albumin) were added to the
upper chamber. The lower chamber contained 0.5 ml of
the same medium. Cells were cultured for 4 h. The inner
Chemotaxicell was cleaned with PBS, and cells were fixed
with 100% methanol at room temperature for 20 min.
The inner cell was cleaned with cotton bar, and the
migrated cells were stained with 1% crystal violet at room
temperature for 30 min., and were washed with H2O. The
cells were extracted with 0.2 ml of 1% SDS with 1% Triton
X-100 for 1 h upon agitation. Then extract of 0.15 ml was
transferred to a 96 well plate and OD 590 nm was deter-
mined. Upon inhibition assay using low molecular weight
compounds, they were dissolved in ethanol and were
added to the lower chamber so that the final ethanol con-
centration was 2%. The control contained also 2% ethanol
in this occasion. Inhibition assay using peptides was per-
formed by adding them dissolved in H2O. Assay was done
in duplicate.
Other methods
Binding activity to midkine was evaluated in the BIA-
CORE 3000 System (GE Healthcare, UK Ltd). A CM5
sensor chip coated with carboxymethyldextran was acti-
vated by injecting a solution (1:1) of 200 mM N-ethyl-N'-
(3-dimethylaminopropyl) carbodiimide hydrochloride
and 100 mM N-hydroxysuccinimide at a flow rate of 10
μl/min. A 70 μl aliquot of midkine solution (50 μg/ml in
10 mM acetate buffer, pH 5.0) was injected for immobili-
zation. The remaining activated N-hydroxysuccinimide
ester groups were blocked by injecting 1 M ethanolamine
hydrochloride/NaOH, pH 8.5, and washed with 10 μl of 1
M NaCl. Peptides (5 μg/ml) in the running buffer (10 mM
HEPES-NaOH, pH 7.4, containing 0.15 M NaCl and
0.0005% Tween 20) were injected into the flow cell, and
the change in resonance units was recorded. Binding
assays were performed at 25°C with a constant flow rate
of 10 μl/ml in both association and dissociation phases.
Docking of α4β1-integrin with midkine was performed
by the Greenpepper program (Chuden CTI) and docking
of low molecular weight compounds in ZINC library
http://zinc.docking.org/ with midkine was performed by
the Presto-X2 program (National Institute of Advanced
Industrial Science and Technology, Tsukuba, Japan).
Results
Design of midkine inhibitory peptides based on interaction 
of midkine with integrin
The three dimensional structure of α4β1integrin was
deduced by homology modeling employing the structure
of αVβ3-integrin [31]. The three dimensional structure of
midkine was determined by NMR [23]. The possible
three dimensional structures were deduced for the com-
plex of the C-terminal half domain of midkine and α4β1-
integrin. Among 50 higher scores one, in 29 cases interac-
tions occurred in relatively exposed area, namely, either
the interacting site in the α-chain is within 450 amino
acid residues from the N-terminal and or interacting site
in the β-chain is within 250 amino acid residues from the
N-terminal. From the amino acid residues expected to be
in the contact sites in the 29 cases, and from the homol-
ogy of αVβ3- and α4β1-integrins, we searched stretch of
amino acids that have multiple contact sites and expected
to be in α-helix or β-sheet structure. The majority of con-
tact sites in the integrin were in expected random coil
structures, but sequences in Table 1 were in the expected
α-helix orβ-sheet structures.
The expected binding sites in the midkine C-terminal
half to α4 β1 integrin were mostly in the three anti-pararel
β-sheets [23]. Thus the following peptides in the β-sheets
were selected as candidate peptide inhibitors derived
from midkine: YKFENWGACDGG (YK12), GTGT-
KVRQGTL (GT11), and QETIRVTKPC (QE10).
By surface plasmon assay, all of the integrin-derived
peptides were found to have significant binding activity
to midkine (Table 1). Then, we tested whether these pep-
tides inhibited midkine activity.
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KANAKSCGECI (KA11) were found to inhibit the
migration activity when added at the concentration of 1
mg/ml to the lower chamber (Table 2). KA11 is derived
from N-terminal region of β1-integrin (Table 1). Mid-
kine-derived YK12 is in an externally located β-sheet.
When the peptides YK12 and KA11 were added to cul-
ture of UMR106 cells at the concentration of 1 mg/ml, no
toxicity was observed, although inhibition of cell-substra-
tum adhesion was observed in a certain occasion.
Search of low molecular weight compounds with inhibitory 
activity
The ZINC library of drug-like compounds were surveyed
in silico for possible binding activity to C-terminal half of
midkine. We selected 100 compounds, which were avail-
able from ChemDiv, one of the suppliers of drug-like
compounds, and were among 531 compounds with the
highest binding score in 300,000 compounds so far sur-
veyed. Among the 100 compounds purchased, 10 com-
pounds were soluble in ethanol at 1 mg/ml, and were not
toxic to L cells after culturing for 24 h at the concentra-
tion of 40 μg/ml. These 10 compounds were surveyed for
the activity to inhibit midkine activity. Consequently, two
compounds, Compound I [2-(2,6-dimethylpiperidin-1-
Table 1: Binding of integrin-derived peptides to midkine
Name Sequence Origin Expected structure Binding constant to midkine (μM)
KQ9 KQNQVKFGS α4 247-255 α-helix 0.20
AM7 AMETNLV α4 359-365 β-sheet 0.95
MQ7 MQSTIRE α4 335-341 β-sheet 0.23
TF8 TFSQRIEG α4 419-426 β-sheet 0.14
KA11 KANAKSCGECI β1 29-39 α-helix 0.27
IE15 IENPRGSKDIKKNKN β1 80-94 β-sheet 0.30
PA9 PAKLRNPCT β1 200-208 α-helix 0.45
Table 2: Inhibitory activities of synthetic peptides and low 
molecular weight compounds to midkine-dependent migration.
Materials Concentration Migration activity (%)
None 100
Peptides
YK12 1 mg/ml 44.0 ± 10.5
GT11 1 mg/ml 156 ± 6
QE10 1 mg/ml 99.5 ± 10.6
KQ9 1 mg/ml 107 ± 15
AM7 1 mg/ml 99.5 ± 6.9
MQ7 1 mg/ml 107 ± 2
TF8 1 mg/ml 105 ± 24
KA11 1 mg/ml 43.7 ± 12.8
IE15 1 mg/ml 113 ± 10.1
PA9 1 mg/ml 69.4 ± 46.1
Low molecular weight 
compounds
Compound I 0.146 mg/ml 43.8 ± 10.2
Compound II 0.10 mg/ml 53.6 ± 4.1
Figure 1 Structure of compounds with midkine inhibitory activi-
ties. A, Compound I; B, Compound II.
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Chem:4603792;ZINC00213280] and Compound II
[ZINC00184372; no PubChem number, no official name]
(Fig. 1) were found to significantly inhibit the activity
(Table 2). They showed no toxicity to the target cells at
the concentration used for the assay. The two compounds
share a common structure, CF3 (Fig. 1). In the model of
the interaction of Compound I with the C-terminal half
of midkine, CF3 faces Lys 65 and Phe 66, which are in the
first β-sheet (Fig 2). In the space filling model, compound
I, the area of which is shown by a white line, also covered
Arg. 81 (marked with an arrow as 1), which forms a key
heparin-binding site [23] (Fig. 2). Mutation of Arg 81
leads to loss of neurite-promoting activity of midkine
[24]. Compound II is also predicted to bind to midkine in
a manner very similar to Compound I, while coverage of
Arg 81 was only partial. (data not shown).
Discussion
A convenient method has been developed to survey
materials that inhibit midkine activity. This method has
been effective to screen peptides and low molecular
weight compounds with the inhibitory activity. An
aptamer, which has midkine inhibitory activity and inhib-
its development of experimental autoimmune encephali-
tis, was also found using the method [7].
Concerning peptides and low molecular weight com-
pounds with midkine binding and midkine inhibitory
activity, these are expected to bind mainly to the first β-
sheet of the C-terminal half domain. Probably, this strand
is exposed and is easier to be bound by the inhibitors, and
through this binding, R81, which is a key amino acid in
midkine activity and comprises a heparin binding site
[23,24], is expected to be covered by the inhibitor. In
addition, a possibility is not excluded that the first β-sheet
itself plays a key role in midkine activity, such as in biding
to integrins. Indeed a peptide derived from the first β-
sheet was found to inhibit midkine activity. It is noted
that the first β-sheet has Trp 69, which forms βC1 bulge
with Arg81, the key residue in heparin-binding, which is
in the centrally located β-sheet [23].
The inhibitory activity of peptides and low molecular
weight compounds described here is not potent, and fur-
ther elaboration is required to obtain materials of poten-
tial clinical utility. However, we think that the present
material might even become seed materials. As an exam-
ple, we noted that a methyl group in Compound I, a mid-
kine inhibitory material, is expected to be located near to
Arg 81 (marked with an arrow as 1 in Fig. 2), a key amino
acid in midkine activity. Thus, conversion of the methyl
group to carboxyl group might enhance the affinity of the
compound to midkine, and increases the inhibitory activ-
ity.
Conclusions
A simple assay procedure was developed for screening of
midkine inhibitors. Inhibitory materials, especially low
molecular weight compounds found by the present study
are expected to become mother compounds to develop
clinically applicable midkine inhibitors.
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